EMD-2286

Tomography
16.6 Å
EMD-2286 Deposition: 18/01/2013
Map released: 30/01/2013
Last modified: 06/02/2013
Overview Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-2286

3D map of another peptide conjugated antibody particle by individual-particle electron tomography (IPET) and optimized negative-staining.

EMD-2286

Tomography
16.6 Å
EMD-2286 Deposition: 18/01/2013
Map released: 30/01/2013
Last modified: 06/02/2013
Overview Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: Peptide-conjugated Human IgG1 Antibody

Deposition Authors: Tong H, Zhang L, Kaspar A, Rames M, Huang L, Woodnutt G, Ren G
Peptide-conjugation induced conformational changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography.
Tong H, Zhang L , Kaspar A, Rames MJ, Huang L, Woodnutt G, Ren G
(2013) SCI. REP. , 3 , 1089 - 1089
Abstract:
Peptides show much promise as potent and selective drug candidates. Fusing peptides to a scaffold monoclonal antibody produces a conjugated antibody which has the advantages of peptide activity yet also has the pharmacokinetics determined by the scaffold antibody. However, the conjugated antibody often has poor binding affinity to antigens that may be related to unknown structural changes. The study of the conformational change is difficult by conventional techniques because structural fluctuation under equilibrium results in multiple structures co-existing. Here, we employed our two recently developed electron microscopy (EM) techniques: optimized negative-staining (OpNS) EM and individual-particle electron tomography (IPET). Two-dimensional (2D) image analyses and three-dimensional (3D) maps have shown that the domains of antibodies present an elongated peptide-conjugated conformational change, suggesting that our EM techniques may be novel tools to monitor the structural conformation changes in heterogeneous and dynamic macromolecules, such as drug delivery vehicles after pharmacological synthesis and development.